Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act

Guidance for Industry

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2014
Procedural

Revision 1

OMB Control No. 0910-0679
Expiration Date: 4/30/2017
See additional PRA statement in section IV of this guidance
Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act

Guidance for Industry

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
druginfo@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2014
Procedural

Revision 1
TABLE OF CONTENTS

I. INTRODUCTION .......................................................................................................................... 1

II. BACKGROUND .......................................................................................................................... 2
   A. Scope of Section 505(q) ........................................................................................................... 2
   B. Determination of Delay ......................................................................................................... 3
   C. Certification and Verification ................................................................................................. 3
   D. Final Agency Action ............................................................................................................... 3
   E. Judicial Review ....................................................................................................................... 4
   F. Exceptions and Reporting ........................................................................................................ 4

III. DISCUSSION ........................................................................................................................... 4
   A. How Does FDA Determine if Section 505(q) Applies to a Particular Petition? .................. 5
      1. Petition Submitted on or after September 27, 2007, or July 9, 2012 ............................... 5
      2. Petition Submitted in Writing and Pursuant to § 10.30 or 10.35 ....................................... 6
      3. ANDA, 505(b)(2) Application, or Biosimilar Application Is Pending at the Time the Petition
         Is Submitted ......................................................................................................................... 6
      4. Petition Requests an Action That Could Delay Approval of a Pending ANDA, 505(b)(2)
         Application, or Biosimilar Application ............................................................................... 8
      5. Petition Does Not Fall Within Any of the Exceptions Described in Section 505(q)(4) ....... 8
   B. How Does FDA Determine if a Petition Would Delay Approval of an ANDA, 505(b)(2)
      Application, or Biosimilar Application? .................................................................................. 8
   C. How Does FDA Apply the Certification Requirements in Section 505(q)(1)(H)? .............. 10
      1. Determination of Whether a Certification Is Complete ....................................................... 10
      2. What a Petitioner Should Do if a Certification Is Deficient .............................................. 12
   D. How Does FDA Apply the Verification Requirements in Section 505(q)(1)(I)? ............... 12
   E. What Is the Relationship Between the Review of Petitions Under Section 505(q) and the
      Review of ANDAs, 505(b)(2) Applications, and Biosimilar Applications for Which the Agency
      Has Not Yet Made a Final Decision on Approvability? ......................................................... 13

IV. PAPERWORK REDUCTION ACT OF 1995 ........................................................................... 14
Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act

Guidance for Industry

I. INTRODUCTION

This guidance provides information regarding FDA’s (or the Agency’s) current thinking on interpreting section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 505(q) of the FD&C Act governs certain citizen petitions and petitions for stay of Agency action that request that FDA take any form of action related to a pending application submitted under section 505(b)(2) or 505(j) of the FD&C Act or a pending application for licensure of a biological product as biosimilar or interchangeable that is submitted under section 351(k) of the Public Health Service Act (PHS Act).

This guidance describes FDA’s interpretation of section 505(q) regarding how the Agency determines if (1) the provisions of section 505(q) addressing the treatment of citizen petitions and petitions for stay of Agency action (collectively, petitions) apply to a particular petition and (2) a petition would delay approval of a pending abbreviated new drug application (ANDA), 505(b)(2) application, or biosimilar application. This guidance also describes how FDA interprets the provisions of section 505(q) requiring that (1) a petition include a certification and (2) supplemental information or comments to a petition include a verification and addresses the

---

1 This guidance has been prepared by the Office of Regulatory Policy in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.
2 21 U.S.C. 355(q). For brevity, in this guidance, references to section 505(q) of the FD&C Act are cited as section 505(q).
3 21 U.S.C. 355(b)(2) and (j). In this guidance, an application submitted under section 505(b)(2) of the FD&C Act is referred to as a 505(b)(2) application and an application submitted under section 505(j) of the FD&C Act is referred to as an abbreviated new drug application (ANDA).
4 42 U.S.C. 262(k). In this guidance, an application submitted under section 351(k) of the PHS Act is referred to as a biosimilar application.
5 Section 505(q)(1)(E) provides that FDA may issue guidance to describe the factors that will be used to determine whether a petition is submitted with the primary purpose of delaying the approval of an application. This guidance does not address the factors under section 505(q)(1)(E). Any guidance issued pursuant to section 505(q)(1)(E) will be issued separately from this guidance. FDA also is planning to issue regulations through notice and comment rulemaking to further implement section 505(q). On Jan. 3, 2012, FDA issued a proposed rule proposing to amend
relationship between the review of petitions and pending ANDAs, 505(b)(2) applications, and biosimilar applications for which the Agency has not yet made a decision on approvability.

This guidance revises the guidance for industry Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act issued in June 2011. This revision updates the June 2011 guidance to reflect the amendments to 505(q) of the FD&C Act made by the Food and Drug Administration Safety and Innovation Act and to update the expiration date for the OMB control number for the collection of information.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

The Food and Drug Administration Amendments Act (FDAAA) was enacted on September 27, 2007. Section 914 of Title IX of FDAAA took effect on the date of enactment and amended section 505 of the FD&C Act by adding a new subsection (q).6

Section 505(q), as enacted by FDAAA, applied to certain petitions that request that FDA take any form of action related to a pending ANDA or 505(b)(2) application and governs the manner in which these petitions are treated.

The Food and Drug Administration Safety and Innovation Act (FDASIA) was enacted on July 9, 2012.7 Section 1135 of FDASIA amended section 505(q) of the FD&C Act in two ways. First, it shortened from 180 days to 150 days FDA’s deadline for responding to petitions subject to section 505(q). Second, with the exceptions noted below, it expanded the scope of section 505(q) to include certain petitions related to biosimilar applications.

The provisions of section 505(q) are described in greater detail below.

A. Scope of Section 505(q)

Section 505(q)(1)(A), together with section 505(q)(5), describes the general scope of section 505(q). Section 505(q)(1)(A) provides:

The Secretary shall not delay approval of a pending application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act because of any request to take any form of action relating to the application, either before or during consideration of the request, unless—

certain regulations relating to citizen petitions, petitions for stay of action, and the submission of documents to FDA (77 FR 25).

(i) the request is in writing and is a petition submitted to the Secretary pursuant to section 10.30 or 10.35 of title 21, Code of Federal Regulations (or any successor regulations); and
(ii) the Secretary determines, upon reviewing the petition, that a delay is necessary to protect the public health.

In section 505(q)(5), the term *application* is defined as an application submitted under section 505(b)(2) or 505(j) of the FD&C Act or 351(k) of the PHS Act and the term *petition* is defined as a request described in 505(q)(1)(A)(i).

### B. Determination of Delay

If FDA determines that a delay of approval of an ANDA, 505(b)(2) application, or biosimilar application is necessary to protect the public health, FDA is required to provide to the applicant not later than 30 days after making the determination:

1. notification that the determination has been made,
2. if applicable, any clarification or additional data that the applicant should submit to the petition docket to allow FDA to review the petition promptly, and
3. a brief summary of the specific substantive issues raised in the petition which form the basis of the determination.8

At FDA’s discretion, the information is to be conveyed by either a document or a meeting with the applicant.9 The information conveyed as part of the notification is to be considered part of the application and subject to the disclosure requirements applicable to information in such application.10

### C. Certification and Verification

Under section 505(q)(1)(H), FDA may not consider a petition for review unless the petition is in writing and signed and contains a certification that is specified in that section. In addition, FDA may not accept for review any supplemental information or comments on a petition unless the submission is in writing and signed and contains a specific verification.11

### D. Final Agency Action

Section 505(q)(1)(F) governs the timeframe for final Agency action on a petition. Under this provision, FDA shall take final Agency action on a petition not later than 150 days after the date on which the petition is submitted. The 150-day period is not to be extended for any reason, including any determination made under section 505(q)(1)(A) regarding delay of approval of an application, the submission of comments or supplemental information, or the consent of the petitioner.

---

8 Section 505(q)(1)(B).
9 Section 505(q)(1)(C).
10 Section 505(q)(1)(D).
11 Section 505(q)(1)(I).
FDA may deny a petition at any point if the Agency determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying the approval of an application and the petition does not on its face raise valid scientific or regulatory issues.\textsuperscript{12} FDA may issue guidance to describe the factors that will be used to determine whether a petition is submitted with the primary purpose of delaying the approval of an application.\textsuperscript{13}

\section*{E. Judicial Review}

Section 505(q)(2) governs judicial review of final Agency action. Section 505(q)(2) does not apply to a petition addressing issues concerning a biosimilar application.\textsuperscript{14}

Under section 505(q)(2)(A), FDA shall be considered to have taken final Agency action on a petition if FDA makes a final decision within the meaning of 21 CFR 10.45(d) during the 150-day period or the 150-day period expires without FDA having made a final decision. Under section 505(q)(2)(B), if a civil action is filed against the Secretary with respect to any issues raised in the petition before final Agency action, a court shall dismiss the action without prejudice for failure to exhaust administrative remedies. Section 505(q)(2)(C) describes the information to be included in the administrative record.

\section*{F. Exceptions and Reporting}

Section 505(q)(4) exempts certain categories of petitions from the provisions of section 505(q) — in particular, petitions relating to 180-day generic drug exclusivity and petitions from a 505(b)(2), ANDA, or biosimilar applicant regarding FDA actions with respect to that application. Section 505(q)(3) and section 914(b) of FDAAA also provide for certain reporting requirements from FDA to Congress.

\section*{III. DISCUSSION}

As described in section II of this guidance, the provisions of section 505(q) addressing the treatment of petitions apply only to certain petitions. These provisions include, for example, the requirements that approval of an ANDA, 505(b)(2) application, or biosimilar application not be delayed by a petition absent an Agency determination that a delay is necessary to protect the public health, the provisions requiring final Agency action on the petition within 150 days of submission, and the provisions requiring a certification or a verification.

We describe below how we determine:

- if the provisions of section 505(q) apply to a particular petition
- if a petition would delay approval of a pending ANDA, 505(b)(2) application, or biosimilar application

We also describe how we interpret:

\textsuperscript{12} Section 505(q)(1)(E).
\textsuperscript{13} Section 505(q)(1)(E). As noted in footnote 5, any guidance issued pursuant to section 505(q)(1)(E) will be issued separately from this guidance.
\textsuperscript{14} Section 505(q)(4)(B).
Contains Nonbinding Recommendations

- section 505(q)(1)(H) requiring that a petition include a certification
- section 505(q)(1)(I) requiring that supplemental information or comments on a petition include a verification

We also describe the relationship between the review of petitions under section 505(q) and the review of ANDAs, 505(b)(2) applications, and biosimilar applications for which the Agency has not yet made a final decision on approvability.

A. How Does FDA Determine if Section 505(q) Applies to a Particular Petition?

We interpret section 505(q) to apply to a petition only if the petition meets all of the following criteria:

- The petition is submitted to FDA on or after September 27, 2007, (if the subject matter of the petition relates to approval of an ANDA or 505(b)(2) application) or on or after July 9, 2012, (if the subject matter of the petition relates to approval of a biosimilar application).
- The petition is submitted in writing and pursuant to 21 CFR 10.30 or 10.35.
- An ANDA, 505(b)(2) application, or biosimilar application is pending at the time the petition is submitted to FDA.
- The petitioner requests an action that could delay approval of a pending ANDA, 505(b)(2) application, or biosimilar application.
- The petition does not fall within any of the exceptions described in section 505(q)(4).

We discuss each criterion in greater detail below.

1. Petition Submitted on or after September 27, 2007, or July 9, 2012

Because section 914 of FDAAA became effective on September 27, 2007, we believe that the provisions of section 505(q) only apply to petitions that are submitted on or after September 27, 2007, (if the subject matter of the petition relates to approval of an ANDA or 505(b)(2) application). We do not believe that section 505(q) applies to any petitions that were submitted before September 27, 2007, because section 505(q) does not state that it applies retroactively to petitions submitted before the effective date. Likewise, we do not believe that section 505(q) applies to any petitions whose subject matter relates to the approval of a biosimilar application if those petitions were submitted before July 9, 2012, because section 505(q) does not state that it applies retroactively to those petitions. In addition, such an interpretation might impose a statutory-day deadline for responding to a petition after the deadline has already passed.\(^\text{15}\)

Even if section 505(q) were interpreted to apply retroactively, FDA would not be able to review any petition submitted before the applicable date because those petitions would not contain the required certification and, as explained in section III.C of this guidance, the statute does not

\(^{15}\) A petition subject to 505(q) that was submitted on or after September 27, 2007, but before July 9, 2012, is subject to the 180-day deadline. A petition subject to section 505(q) that was submitted on or after July 9, 2012, is subject to the 150-day deadline.
permit a petitioner to cure the deficiency by supplementing a petition to add the certification to the petition.

2. **Petition Submitted in Writing and Pursuant to § 10.30 or 10.35**

Under section 505(q) of the FD&C Act, a petition must be submitted in writing and pursuant to § 10.30 or 10.35. Section 10.30 of our regulations describes FDA’s general requirements for submitting a citizen petition, and § 10.35 describes our requirements for submitting a request for administrative stay of action. If these criteria are not met, we will not consider section 505(q) to apply to the petition.

We note that communications with the Agency regarding any issues intended to delay the approval of an ANDA, 505(b)(2) application, or biosimilar application (regardless of whether the communications are considered to be petitions subject to section 505(q)) are appropriately submitted through the petition process pursuant to § 10.30 or 10.35 rather than as correspondence to the NDA, ANDA, 505(b)(2) application, biosimilar application, or another process. Similarly, any communications regarding a citizen petition should be filed as comments in the appropriate docket, not to the NDA, ANDA, 505(b)(2) application, or biosimilar application.

We also remind persons that they may not cross-reference or rely upon information that is not included in the petition. Under §§ 10.30(b) and 10.35(b), petitions must be submitted in accordance with 21 CFR 10.20. Section 10.20(c) requires that “[i]nformation referred to or relied upon in a submission is to be included in full and may not be incorporated by reference, unless previously submitted in the same proceeding.” In addition, the certification required for petitions subject to section 505(q) (described in section III.C of this guidance) and the certification required for citizen petitions under § 10.30(b) require the petitioner to certify that “this petition includes all information and views upon which the petition relies.” A petition therefore is required to include all information referred to or relied upon by the petitioner. In addition, the petition should contain all information, both favorable and unfavorable, regarding the petitioner’s claims.

3. **ANDA, 505(b)(2) Application, or Biosimilar Application Is Pending at the Time the Petition Is Submitted**

Section 505(q)(1)(A) describes the scope of section 505(q) (see section II of this guidance). Section 505(q)(1)(A) specifically references pending applications and contemplates the possibility that approval could be delayed by issues raised in a petition. Therefore, we interpret section 505(q) to apply only to petitions for which, at the time the petition is submitted, at least one ANDA, 505(b)(2) application, or biosimilar application related to the subject matter of the petition is pending. If there is no related ANDA, 505(b)(2) application, or biosimilar

---

16 Although the existence of a pending application generally is not made public by FDA, a potential petitioner may be aware of the existence of a pending ANDA or 505(b)(2) application, because of (1) a paragraph IV patent notification, from the applicant to the new drug application (NDA) holder and the patent owner, stating that the application has been submitted and explaining the factual and legal bases for the applicant’s opinion that the patent is invalid or not infringed (see section 505(b)(2)(B) and (j)(2)(B) of the FD&C Act), (2) a public announcement by the applicant disclosing the submission of the application, or (3) the tentative approval of an ANDA or 505(b)(2)
application pending at the time that the petition is submitted, then we will not consider the provisions of section 505(q) to apply to the petition. We believe this interpretation is appropriate because if no related ANDA, 505(b)(2) application, or biosimilar application is pending at the time that a petition is submitted, the references in section 505(q)(1)(A) to a pending application and delay of approval by a petition would be inapplicable.

We also believe our interpretation is appropriate to ensure the fair and orderly implementation of section 505(q). Because application of the provisions of section 505(q) flows from a determination that a petition is within the scope of section 505(q), the evaluation of whether a related ANDA, 505(b)(2) application, or biosimilar application is pending needs to be made at the time that the petition is submitted. If we were to take a “rolling” evaluation approach, the status of the petition could change at any time from (1) a petition that is not subject to section 505(q) to one that is subject to section 505(q) should a related ANDA, 505(b)(2) application, or biosimilar application be submitted before we have taken final Agency action on the petition or (2) a petition that is subject to section 505(q) to one that is not subject to section 505(q) if the related ANDA(s), 505(b)(2) application(s), or biosimilar application(s) are subsequently withdrawn or approved and there are no longer any related applications pending. Such a change in the status of the petition would disrupt the orderly application of the provisions of section 505(q) and the Agency’s processing of the petition and also could prejudice petitioners and commenters.

For example, as described in sections III.C and D of this guidance, to be reviewed by FDA, any petition subject to section 505(q) must include a certification and any comments to a petition subject to section 505(q) must include a verification. If, after submission, a petition’s status were converted from not being subject to section 505(q) to being subject to section 505(q), a petitioner who did not include a certification in the petition and/or commenter who did not include a verification in the comments would be prejudiced because the petition or the comments would not be eligible for review by FDA.

For these reasons, we interpret section 505(q) to apply only to petitions for which, at the time the petition is submitted, at least one ANDA, 505(b)(2) application, or biosimilar application related to the subject matter of the petition is pending. We recognize that petitioners may not be aware of the existence of a pending application. Therefore, we encourage all petitioners challenging the approvability of a possible ANDA, 505(b)(2) application, or biosimilar application to include the certification required in section 505(q)(1)(H).

application made public by FDA or the applicant. In addition, FDA’s Web site identifies drug products for which the Agency has received an ANDA with a paragraph IV certification. A potential petitioner may be aware of the existence of a pending biosimilar application because of (1) patent information exchanged under provisions of section 351(l) of the PHS Act, (2) information made available from patent infringement proceedings between a biologics license application (BLA) holder and biosimilar applicant, (3) a public announcement by the applicant disclosing the submission of the application, or (4) the tentative approval of a biosimilar application made public by FDA or the applicant.
4. **Petition Requests an Action That Could Delay Approval of a Pending ANDA, 505(b)(2) Application, or Biosimilar Application**

As noted, section 505(q)(1)(A) contemplates the possibility that approval of a pending ANDA, 505(b)(2) application, or biosimilar application could be delayed by issues raised in the petition. Therefore, we interpret section 505(q) to apply only to petitions that request an action that could delay approval of a pending ANDA, 505(b)(2) application, or biosimilar application. If the action requested by the petition could not delay approval of the application under any reasonable theory, we will not consider the provisions of section 505(q) to apply to the petition.

5. **Petition Does Not Fall Within Any of the Exceptions Described in Section 505(q)(4)**

Section 505(q)(4) provides that section 505(q) will not apply to any petitions that:

1. relate solely to the timing of approval of an application pursuant to the 180-day exclusivity provision at section 505(j)(5)(B)(iv) of the FD&C Act, or
2. are from the sponsor of the ANDA, 505(b)(2) application, or biosimilar application and seek only to have FDA take or refrain from taking any action with respect to that application.

If either of these exceptions applies, we will not consider the provisions of section 505(q) to apply to the petition.

B. **How Does FDA Determine if a Petition Would Delay Approval of an ANDA, 505(b)(2) Application, or Biosimilar Application?**

Under section 505(q)(1)(A), FDA shall not delay approval of an ANDA, 505(b)(2) application, or biosimilar application because of a petition unless the Agency determines that a delay is necessary to protect the public health. To implement this provision, first we determine if the provisions of section 505(q) apply to the petition based on the criteria described in section III.A of this guidance. If the provisions apply, we then determine if the petition may be summarily denied as described in section 505(q)(1)(E) (which allows denial of a petition that was submitted with the primary purpose of delaying approval of an application and does not on its face raise valid scientific or regulatory issues).

If we do not find that the petition may be summarily denied, we will determine if the petition would be the cause of a delay in an approval of an ANDA, 505(b)(2) application, or biosimilar application by using a *but for* test. In other words, would the ANDA, 505(b)(2) application, or biosimilar application be ready for approval but for the issues raised by the petition?

---

17 We note that there are means other than submission of a petition by which interested persons can express their views on issues related to bioequivalence. FDA has been posting draft product-specific bioequivalence recommendations on its Web site at [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm) and announcing in a *Federal Register* notice the availability of these recommendations and the opportunity for the public to consider and comment on the recommendations. We encourage interested persons to submit any comments related to bioequivalence issues in response to a *Federal Register* notice announcing the recommendations.
• If, regardless of the petition, the ANDA, 505(b)(2) application, or biosimilar application would not be ready for approval, then section 505(q)(1)(A) would not be implicated.18

• If the ANDA, 505(b)(2) application, or biosimilar application would be ready for approval but for the petition, then we would next determine if a delay of approval is necessary to protect the public health.

We determine if a delay of approval is necessary to protect the public health based on our preliminary evaluation of the issues raised in the petition. The Agency considers the following:

If the application were approved before the Agency completed the substantive review of the issues in the petition and, after further review, the Agency concluded that the petitioner’s arguments against approval were meritorious, could the presence on the market of drug products that did not meet the requirements for approval negatively affect the public health?

If, after undertaking this analysis, we conclude that the public health could be negatively affected, the Agency will conclude that a delay “is necessary to protect the public health” and will delay approval of the pending application. Issues that could implicate the public health include, for example, (1) whether a proposed generic drug product is bioequivalent to the reference listed drug or (2) whether an indication can be safely omitted from the labeling because that indication is protected by a patent.

If we determine that a delay is necessary, we will notify the applicant as required by section 505(q)(1)(B) and (C) of the FD&C Act. Under these provisions, we are required to provide the following information to the applicant not later than 30 days after making the determination:

• Notification that the determination has been made
• If applicable, any clarification or additional data that the applicant should submit to the petition docket to allow FDA to review the petition promptly
• A brief summary of the specific substantive issues raised in the petition which form the basis of the determination

At our discretion, we will convey this information to the applicant by either a letter or a meeting with the applicant.19 As provided in section 505(q)(1)(D), we will consider the information conveyed in the notification to be part of the application and subject to the disclosure requirements applicable to information in such application. We do not intend to notify the petitioner if a determination has been made that a delay in approval of an application is necessary to protect the public health because the provisions of section 505(q) do not require such a notification to the petitioner. We will resolve any public health issues before approving the application. If we, in the course of considering the petition, later determine that a delay of

---

18 We note, however, that a petition would still be subject to section 505(q) as long as a relevant application is pending at the time the petition is submitted.

19 See section 505(q)(1)(C).
approval is no longer necessary to protect the public health, we will proceed with approving the application.

Regardless of whether we determine that a delay of approval of an application is or is not necessary to protect the public health, we will continue to consider the 150-day period for final Agency action under section 505(q)(1)(F) to apply to the petition.

C. How Does FDA Apply the Certification Requirements in Section 505(q)(1)(H)?

Section 505(q)(1)(H) of the FD&C Act provides that FDA shall not consider a petition for review unless the petition is in writing and signed and contains the following certification:

I certify that, to my best knowledge and belief: (a) this petition includes all information and views upon which the petition relies; (b) this petition includes representative data and/or information known to the petitioner which are unfavorable to the petition; and (c) I have taken reasonable steps to ensure that any representative data and/or information which are unfavorable to the petition were disclosed to me. I further certify that the information upon which I have based the action requested herein first became known to the party on whose behalf this petition is submitted on or about the following date: ________ [in the blank space, provide the date on which such information first became known to such party]. If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: ________ [in the blank space, provide the names of such persons or organizations]. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition.

This certification includes statements in addition to those described under § 10.30(b) for the certification in citizen petitions.

We apply section 505(q)(1)(H) to require that all petitions that fall within the scope of section 505(q) be in writing and signed, and contain the complete 505(q) certification to be considered for review by FDA. If, based on the criteria described in section II.A of this guidance, section 505(q) applies to the petition, but the petition is not in writing or signed, or does not contain the complete certification, we will not review the petition.

1. Determination of Whether a Certification Is Complete

As part of our determination of whether a petition contains the complete 505(q) certification, we will evaluate whether (1) the language of the certification in the petition exactly mirrors the language provided in section 505(q) and (2) the petitioner provided a date on which the information first became known to the party on whose behalf the petition is submitted. Because section 505(q) sets forth the exact words to be used in the certification, we will consider a certification to be deficient if every word in the petitioner’s certification does not match every word of the certification provided in section 505(q). In other words, the petitioner’s certification must correspond verbatim to the certification in section 505(q). For example, if, rather than using the phrase “first became known to the party on whose behalf this petition is submitted,” the petitioner substitutes the phrase “first became known to me,” we will consider the certification to
be deficient. We believe this interpretation is mandated by the statutory language because section 505(q) specifies the exact text of the certification.

Section 505(q) also requires that the petitioner provide in the certification the date on or about which the information first became known to the party. Section 505(q) includes a blank space in the certification for that information. We consider a “date” to include a month, day, and year. Therefore, we will consider a certification to be deficient if the petitioner has not provided the month, day, and year on or about which the information first became known to the party on whose behalf the petition is submitted. For example, if the petitioner provides “May 2010” as the date in the certification, we would consider the certification to be deficient. The text of the certification provided in section 505(q) includes a qualification that the petitioner learned of the information “on or about the following date.” Therefore, we believe the certification would accommodate instances in which a petitioner may not know the exact date on which it became aware of the information. To the extent that a petitioner believes further explanation of the date is needed, we believe that the blank space in the certification allows for the insertion of additional information. In addition, there may be instances in which different types of information became known to the petitioner over a period of time. In that case, the petitioner should provide each estimated relevant date and identify the information associated with the particular date. We caution that when adding information, the petitioner should ensure that the words of the certification (except for what is provided in the blank space) continue to exactly match the words of the certification as provided by section 505(q).

For example, a certification that we would consider to be complete and acceptable could include additional information explaining the petitioner’s specified date or dates as follows:

I certify that, to my best knowledge and belief: (a) this petition includes all information and views upon which the petition relies; (b) this petition includes representative data and/or information known to the petitioner which are unfavorable to the petition; and (c) I have taken reasonable steps to ensure that any representative data and/or information which are unfavorable to the petition were disclosed to me. I further certify that the information upon which I have based the action requested herein first became known to the party on whose behalf this petition is submitted on or about the following date: September 21, 1995 (information about bioavailability issues with the innovator drug); November 12, 2009 (publication of a draft bioequivalence guidance for the drug); March 30, 2010 (information that an ANDA had been submitted). If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: Company A. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition.
2. What a Petitioner Should Do if a Certification Is Deficient

We also interpret section 505(q)(1)(H) to require that the certification be included in the original petition. Section 505(q)(1)(H) refers to the “petition” as the subject document that must contain the certification. Because sections 505(q)(1)(E) and 505(q)(1)(I) distinguish between petitions and supplements to petitions, the reference to a petition in section 505(q)(1)(H) refers only to the original petition and not to a supplement. Therefore, if a petition is missing the complete certification, we will not permit a petitioner to cure the deficiency by submitting a supplement to add the certification to the petition.

If a petitioner has submitted a petition that is missing the required certification but is otherwise within the scope of section 505(q) and the petitioner would like FDA to review the petition, the petitioner should (1) submit a letter withdrawing the deficient petition pursuant to § 10.30(g) and (2) submit a new petition that contains the certification. In this case, the provisions of section 505(q) governing the treatment of petitions will apply only to the new petition that includes the required certification because we cannot review the deficient petition under section 505(q)(1)(H). In particular, we consider the 150-day timeframe for FDA to respond to the petition to begin from the date of submission of the new, complete petition and not the original, deficient petition.

Because FDA will not review a petition that is subject to section 505(q) but is missing the required certification, all petitioners raising issues that could delay the approval of a possible ANDA, 505(b)(2) application, or biosimilar application should include the certification in their petitions to ensure FDA consideration. Although we may contact a petitioner to notify him or her of a missing or deficient certification, we note that it is the responsibility of the petitioner to ensure that its petition complies with the applicable requirements of section 505(q), as well as all other applicable statutory and regulatory requirements.

D. How Does FDA Apply the Verification Requirements in Section 505(q)(1)(I)?

Section 505(q)(1)(I) provides that FDA shall not accept for review any supplemental information or comments on a petition unless the supplemental information or comments are in writing, signed, and contain the following verification:

I certify that, to my best knowledge and belief: (a) I have not intentionally delayed submission of this document or its contents; and (b) the information upon which I have based the action requested herein first became known to me on or about _________ [in the blank space, provide the date on which such information first became known to such party]. If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: ________ [in the blank space, provide the names of such persons or organizations]. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition.

---

20 Section 505(q)(1)(E) states that if FDA determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying approval of an application, the Agency may deny the petition at any point. Section 505(q)(1)(I) requires that supplemental information include a verification as described in section III.D of this guidance.
Section 505(q)(1)(I) applies to any supplemental information or comments that are submitted to a petition that is subject to section 505(q). If any such supplemental information or comments do not include the required verification, FDA will not review the submission. As with our approach to the certification as explained in section III.C of this guidance, we will consider a verification to be deficient if it does not exactly mirror the words of the verification in section 505(q)(1)(I) of the FD&C Act or if the petitioner or commenter does not provide a month, day, and year for the “date” in the verification.

If a petitioner or commenter has submitted supplemental information or comments without the required verification or with an incomplete verification and the petitioner or commenter would like FDA to review the submission, the petitioner or commenter should resubmit the supplemental information or comments with the required verification to FDA.

For petitions that are subject to section 505(q), because FDA will not review any supplemental information or comments that are missing the required verification, all petitioners or commenters should include the verification in their supplemental information or comments to a petition that includes the 505(q) certification to ensure FDA consideration. Petitioners and commenters should not rely on FDA reviewers to notify them that their supplements or comments will not be reviewed because of a missing or deficient verification. In some instances, FDA receives numerous supplements and comments in a docket, and it would be administratively burdensome to monitor all the dockets for 505(q) petitions and notify commenters about the statutory requirement. It is the responsibility of petitioners and commenters to ensure that their supplemental information or comments comply with the applicable requirements of section 505(q), as well as all other applicable statutory and regulatory requirements.

E. What Is the Relationship Between the Review of Petitions Under Section 505(q) and the Review of ANDAs, 505(b)(2) Applications, and Biosimilar Applications for Which the Agency Has Not Yet Made a Final Decision on Approvability?

A petition may request that FDA take an action related to a specific aspect of a pending ANDA, 505(b)(2) application, or biosimilar application for which the Agency will not have made a final decision regarding approvability by the date that the petition response is due. As described in section II.D., section 505(q)(1)(F) requires FDA to take final Agency action on a petition within 150 days of submission. The review of applications that may be affected by the petition is governed by a separate review process, which will not necessarily be completed by the date the petition response is due. If a petition requests that the Agency take an action related to a specific aspect of a pending application, we will consider the review status of the affected application(s) in determining whether it would be appropriate for the Agency to respond to the request to take the action requested in the petition within the 150-day timeframe.

The provisions in section 505 of the FD&C Act and FDA’s regulations at 21 CFR part 314 establish certain procedures by which the Agency reviews an NDA or ANDA and notifies an applicant if it determines that an application is approved (§ 314.105) or may not be approved (section 505(c) and 505(j); §§ 314.125 and 314.127), or identifies the deficiencies in the application and the steps an applicant may take to respond to the deficiencies (§ 314.110). In addition, the statute and regulations describe a specific process through which an applicant whose application the Agency has found not to meet the requirements for approval may
challenge the Agency’s determination (section 505(c)(1)(B) and (d), 505(j)(5)(E); § 314.200).
Under this process, the Agency must give the applicant notice of an opportunity for a hearing on whether the application is approvable, with a specific timeframe and process should the applicant request such a hearing. These procedures ensure that applicants have an adequate opportunity to challenge a finding by the Agency that a product does not meet the requirements for approval.

By contrast, responses to citizen petitions, including petitions subject to section 505(q), constitute final Agency action and are subject to immediate review by the courts. They therefore carry with them none of the procedural rights for the affected applicants that attach to a decision to deny approval of an application. If we were to respond substantively to a petitioner’s request regarding the approvability of a certain aspect of a pending application before we have taken a final action on the approvability of the application as a whole, such response could interfere with the statutory and regulatory scheme governing the review of applications and related procedural rights of applicants. There is no evidence that in enacting section 505(q), Congress intended to limit applicants’ procedural rights by requiring that the Agency make decisions that constitute final Agency action on the approvability of specific aspects of a pending application (e.g., the acceptability of a proposed trade name, specific claims proposed in a drug product’s labeling) on a piecemeal basis outside of the process established under the FD&C Act and regulations.

Therefore, we do not interpret section 505(q) to require a substantive final Agency decision within 150 days on the approvability of a specific aspect of a pending application when a final decision on the approvability of the application as a whole has not yet been made and when to render such a decision could deprive an applicant of procedural rights established by statute and regulations. In such a situation, we would expect to deny a petition without comment on the substantive approval issue.

IV. PAPERWORK REDUCTION ACT OF 1995

This guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).

The time required to complete this information collection is estimated to average 30 minutes to prepare a certification under section 505(q)(1)(H) of the FD&C Act for citizen petitions and petitions for stay of action, 30 minutes to prepare a verification under section 505(q)(1)(I) of the

---

21 We also note that under applicable statutory and regulatory provisions, we are generally prohibited from disclosing information regarding applications that have not yet been approved. Depending upon the nature and specificity of a petition, these limitations on disclosure also may circumscribe the Agency’s ability to respond substantively to issues raised in a petition that affect a pending application.

22 In the past, we have responded to requests related to general standards for approval (e.g., bioequivalence criteria for generic drug products or the appropriateness of omitting certain protected information from proposed drug product labeling) that may pertain to one or more pending drug applications, without commenting on the approvability of any particular aspect of a specific pending application. We distinguish our approach of responding to petitions that involve general policies or standards for approval of a drug application from our approach described above, which applies to petitions that involve narrow issues of approvability of a specific aspect or aspects of a pending application. We will continue to evaluate each citizen petition on a case-by-case basis with respect to the appropriateness of responding to the petitioner’s requests vis-à-vis any pending applications.
FD&C Act for supplements and comments to citizen petitions and supplements and comments to petitions for stay of action, and 30 minutes to prepare a letter withdrawing a deficient petition for stay of action that is missing the required certification. These estimates include the time to review instructions, search existing data sources, gather the data needed, and complete and review the information collection. Send comments regarding this burden estimate or suggestions for reducing this burden to

Office of Regulatory Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg 51, rm 6223, Silver Spring, MD 20993-0002.

This guidance also refers to previously approved collections of information found in FDA regulations. The collections of information in 21 CFR 10.20, 10.30, and 10.35 have been approved under OMB Control Number 0910-0183, and the collections of information in 21 CFR 314.54, 314.94, and 314.102 have been approved under OMB Control Number 0910-0001.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0910-0679 (expires 4/30/2017).